Our current study uses multiple ER+ breast cancer models and suggests that treatment with tamoxifen may sensitize cell and xenograft models to RT in vitro through the inhibition of dsDNA repair in an NHEJ-dependent manner as well as an increase in the induction of senescence with RT in combination with ET. Here, ESR1 is linked to breast carcinoma.